Lead Product(s): Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: BlueRock Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 21, 2020
Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.